Tesamorelin + Ipamorelin
Sold under one name at three different ratios, and the approved evidence belongs to only one half.
This is the same two-door logic as the classic GH pairing, with tesamorelin swapped in for CJC-1295. The swap buys you an FDA approval. It also changes what you are paying for, and the premixed vials do not agree on how much of each you get.
The classic pairing, with the approved compound swapped in.
Growth hormone reaches the bloodstream through two doors. One compound raises how much the pituitary will release, the other triggers the release. Taking one from each is the standard argument, and it is the same logic behind CJC-1295 with ipamorelin.
What changes here is the GHRH half. Tesamorelin is the only compound in this whole category with an FDA approval attached, and that approval is specifically about reducing deep abdominal fat. People choose it over CJC-1295 for that reason.
Ipamorelin's job is unchanged. It fires the pulse, and it is picked over older compounds in its class because it does so without dragging up cortisol and prolactin.
Its own human record is worth knowing. Helsinn Therapeutics ran two Phase 2 trials of ipamorelin enrolling 437 patients between them, both for recovery of bowel function after surgery (NCT00672074 and NCT01280344). Neither found a significant benefit against placebo.[7] The CJC pairing page covers that record in full.
Four benefits, and how well each one holds up.
The top row is real and it belongs to tesamorelin on its own, measured in a population almost nobody buying this belongs to. The bottom row is the one the product exists to deliver.
Three questions, answered before anything else.
One product name, three formulations.
Where vendors publish amounts, the premixed vials do not agree with each other.[4]
The ipamorelin share more than doubles between the narrowest and widest. Somebody buying the 12 to 2 formulation is getting less than half the ipamorelin of somebody buying the 10 to 5, for the same product name.
Compare that with the CJC pairing, where every vendor publishing amounts sells an even 5 mg of each. That blend gives you what the name implies. This one does not, and there is no way to tell from the label which version you have.
Real evidence, for one compound and one condition.
Tesamorelin was approved in November 2010 for reducing excess abdominal fat in adults with HIV-associated lipodystrophy, a condition where body fat moves into an unusual pattern. That is the whole indication.
Pooled across two Phase 3 trials of 806 participants, visceral fat fell about 15 percent against placebo over 26 weeks.[1] In absolute terms that came to roughly one kilogram and two centimetres of waist.
Two things get lost when that number is quoted for a blend. The headline figures come from tesamorelin on its own at a set dose. No combination was involved.[2] And the people measured were patients with a diagnosed condition rather than healthy or athletic adults.
Adding ipamorelin is expected on mechanism grounds to raise the growth hormone pulse. No trial has quantified what that adds to fat loss, lean mass or recovery in a stack.[2]
Stop taking it and the fat comes back.
Tesamorelin does not change anything structural. It holds growth hormone pulses elevated, and the fat responds while that continues.
The visceral fat reduction is partially reversed within 6 to 12 months of stopping, and that is documented in the trial literature rather than inferred.[3]
So a course is a commitment. Holding a one-kilogram result means continuous use, and no long-term cardiovascular safety data exists to sit alongside that decision.
Blood sugar is the other thing to watch. Fasting glucose and A1C rose in the tesamorelin trials, and the label advises considering stopping if blood sugar problems develop. A1C is a blood test showing average blood sugar over the previous few months.
The only way to know your ratio is to buy two vials.
On most blends the trade is convenience against control. Here there is a third thing at stake, because the ratio is not consistent between vendors.
One vial means mixing powder once instead of twice, one thing to store, and fewer punctures. That is a real advantage and it does not depend on any price argument.
Against that, you cannot tell which of the three formulations you have. Buying tesamorelin and ipamorelin separately costs less on the sticker, lets you set the balance yourself, and is the only route where you know what you are taking.
The same choice on the CJC pairing is easier, because that blend is an even split wherever amounts are published.
One approved compound, one restricted one.
Tesamorelin has a genuine FDA approval as Egrifta, granted in November 2010. It covers one condition, and every other use is off-label.
Ipamorelin has no approved label anywhere. The FDA keeps a register of ingredients compounding pharmacies may work with, called the 503A list, and ipamorelin sits in Category 2 on it, the tier that means not allowed.[5]
A premixed vial inherits the stricter position. Nothing containing ipamorelin can be compounded, whatever the status of the other half, so the approved product and the blend sold online are different things bought through different channels.
Everything sold as a research chemical is unapproved material regardless of which compound is in it.
Blood sugar, and a marker worth measuring.
Both compounds raise your own growth hormone, and growth hormone drives the liver to produce IGF-1. That is the marker people track to check any of this is working.
In a Phase 2 trial of tesamorelin, IGF-1 rose about 53 percent against roughly 5 percent in the comparison group.[6] That is one compound on its own, and this stack raises the same hormone from two directions. The long-term consequences of holding IGF-1 high are not established.
Fasting glucose and A1C rose in the tesamorelin trials, and the label advises caution and says to consider stopping if blood sugar problems or diabetes develop.
Raising growth hormone reduces insulin sensitivity generally, which is why the same warning attaches to MK-677. Anyone taking this has a specific reason to have IGF-1 and fasting glucose checked, and that is a conversation for a doctor.
What people ask about this stack
Is tesamorelin better than CJC-1295 here?
Tesamorelin has an FDA approval and CJC-1295 does not, which is the whole reason people swap it in. The approval covers reducing excess abdominal fat in adults with HIV-associated lipodystrophy, so it describes a population most buyers do not belong to. CJC-1295 has a randomised trial in 65 healthy adults showing large growth hormone and IGF-1 rises, though it measured no clinical outcome. Different kinds of evidence, neither answering the question people are asking.
Why do blends of this vary so much?
Nobody has standardised it. Among vendors who publish amounts, the most common formulation is 10 mg of tesamorelin to 3 mg of ipamorelin. Others sell 10 to 5, and 12 to 2. The ipamorelin share ranges from 14 percent to 33 percent depending on who you buy from, and nothing on the label tells you which you have.
How much belly fat does it shift?
Tesamorelin on its own cut visceral fat about 15 percent against placebo across two Phase 3 trials of 806 participants. That came to roughly one kilogram over six months, and about two centimetres off the waist. Those figures come from tesamorelin on its own in a patient population. No blend was tested, and no healthy adults were measured. What ipamorelin adds has never been quantified.
Does the effect last after stopping?
No. The visceral fat reduction is partially reversed within 6 to 12 months of discontinuation, which is documented in the trial literature. Tesamorelin holds growth hormone pulses elevated rather than changing anything structural, so keeping the result means continuous use.
Blend or separate vials?
Separate vials cost $37.56 for 4 mg total and let you set the ratio. The blend costs $88.00 for 13 mg, which is cheaper per milligram but more than double the sticker, and locks you into whichever of the three ratios that vendor uses. Given how much those ratios differ, buying separately is the only way to know what you are taking.
What should be monitored?
IGF-1 and fasting glucose. Both compounds raise growth hormone, which raises IGF-1, and the long-term consequences of holding it high are not established. Fasting glucose and A1C rose in the tesamorelin trials, and the label advises considering stopping if blood sugar problems or diabetes develop. That is a conversation for a doctor. Compare against the other stacks.
What this page is built on
- 01Falutz et al., the Phase 3 trials that supported tesamorelin's approval in HIV-associated lipodystrophy. Pooled analysis of 806 participants, visceral adipose tissue reduced approximately 15 percent against placebo at 26 weeks. The New England Journal of Medicine report of the same programme is at DOI 10.1056/NEJMoa072375.
- 02Tesamorelin and ipamorelin stack review. Source for the headline visceral fat figures coming from tesamorelin monotherapy rather than the combination, for the absence of any trial quantifying what ipamorelin adds, and for ipamorelin being chosen over other compounds in its class for its side effect profile.
- 03Growth hormone peptides guide. Source for the visceral fat reduction being partially reversed within 6 to 12 months of discontinuation, documented in the clinical trial literature, and for reductions of approximately 15 to 18 percent over 26 weeks.
- 05Ipamorelin's position on the FDA 503A Category 2 list, which bars compounding pharmacies from using it.
- 06Phase II trial of tesamorelin for cognition in ageing HIV-infected persons. NCT02572323. IGF-1 rose 53.2 percent in the immediate group against 5.3 percent in the deferred group at week 24.
- 07Ipamorelin Phase 2 trial record, both run by Helsinn Therapeutics for postoperative ileus. NCT00672074, 117 patients, completed December 2009, outcome recorded as negative. NCT01280344, 320 patients following bowel resection, completed May 2014, no significant differences in measurable motility against placebo.
- 04Peptide Decoding vendor pricing data, 16 September 2026. Lowest in-stock single-compound listings: tesamorelin $20.00, ipamorelin $17.56. Premixed blend from $88.00 for 13 mg. Three distinct compositions parsed from vendor listings: 10/3 mg on five listings, 10/5 mg on one, 12/2 mg on one.